A comprehensive view of Investigational New Drug Application (INDA). This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca announces FDA decision to grant priority review for supplemental New Drug Application for Lynparza tablets in combination with abiraterone and prednisone or prednisolone; combination is a treatment for castration-resistant prostate cancer
Published: August 26, 2022 by AstraZeneca AB
FDA accepts Angion’s IND application for clinical development of biopharmaceutical ANG-3070 oral tyrosine kinase inhibitor to treat idiopathic pulmonary fibrosis; Angion to start enrollment in Phase 1B study, with 20 patients in crossover design trial
Published: May 17, 2022 by GlobeNewswire
Aptar Pharma announces use of the VP3 multidose device as delivery system for Glenmark’s Ryaltris nasal spray, which is being developed for treatment of seasonal allergic rhinitis
Published: January 27, 2022 by AptarGroup Inc.
BetterLife Pharma plans filing of an Investigational New Drug application for its psychedelic-based treatment for major depressive disorder; company plans to initiate clinical trials by Q3 of 2022
Published: January 26, 2022 by Globe Newswire

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count